Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

984
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
984
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.0K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.0K
Principles of Disease Surveillance01:26

Principles of Disease Surveillance

479
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
479
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.0K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

836
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
836
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

423
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
423

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Imagining Genomics and Population Health in 2050: Anticipating Future Research, Policy, and Governance Needs.

Public health genomics·2026
Same author

A Narrative Review of C3 Glomerulopathy: From Pathogenesis to Targeted Therapy.

Canadian journal of kidney health and disease·2026
Same author

Medical device development and innovation for rare and pediatric populations: a global landscape overview.

Orphanet journal of rare diseases·2026
Same author

Systematic identification of rare disease patients in electronic health records enables evaluation of clinical outcomes.

Scientific reports·2026
Same author

Anonymization, accountability, and access: legal dimensions of health data sharing in federated networks. Perspectives from empirical study.

Frontiers in digital health·2026
Same author

What patients value in data reuse for oncology research: a multi-stakeholder qualitative study to inform the European Health Data Space implementation in Belgium and beyond.

Archives of public health = Archives belges de sante publique·2026

Related Experiment Video

Updated: Jan 21, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.2K

Model consent clauses for rare disease research.

Minh Thu Nguyen1, Jack Goldblatt2, Rosario Isasi3

  • 1Center of Genomics and Policy, McGill University, Montreal, Quebec, H3A 0G1, Canada. thu.nguyen@mcgill.ca.

BMC Medical Ethics
|August 3, 2019
PubMed
Summary

Model consent clauses for rare disease research were developed to improve data sharing and participant protection. These clauses aim to harmonize global research efforts and enhance ethical data use for rare disease studies.

Keywords:
Consent clausesCore consent elementsInformed consentRare diseasesResearch ethics

More Related Videos

Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease
07:22

Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease

Published on: November 8, 2017

10.6K
Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.3K

Related Experiment Videos

Last Updated: Jan 21, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.2K
Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease
07:22

Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease

Published on: November 8, 2017

10.6K
Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.3K

Area of Science:

  • Genetics and Genomics
  • Bioethics
  • Medical Research

Background:

  • Rare disease research has advanced significantly due to new technologies and collaborative efforts.
  • Improved data sharing and interoperability are crucial for maximizing research impact.
  • There is a need for standardized consent clauses in rare disease research to ensure ethical and legal data use and participant protection.

Purpose of the Study:

  • To develop model consent clauses specifically for rare disease research.
  • To create comprehensive, harmonized, accessible, and internationally applicable consent clauses.
  • To facilitate participant recruitment and consent in global rare disease studies.

Main Methods:

  • A global Task Force was established to develop the model consent clauses.
  • Existing consent forms and notices were analyzed and categorized by consent themes.
  • The International Rare Diseases Research Consortium (IRDiRC) and Global Alliance for Genomics and Health (GA4GH) Model Consent Clauses (MCC) Task Force convened to design the clauses.

Main Results:

  • Generic core consent elements were identified.
  • Specific core elements for rare disease research were designed, including clauses on familial participation, data sharing, recontact, data linkage, return of results, and incapacity/death.
  • The developed clauses address key considerations in rare disease research.

Conclusions:

  • The model consent clauses provide a tool to foster harmonization and collaboration in rare disease research.
  • These clauses are designed to align with current trends in rare disease research.
  • They aim to enhance the ethical and legal framework for rare disease data and participant protection.